Jefferies Financial Group Inc. Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Key Points

• Jefferies Financial Group Inc. increased its holdings in Oruka Therapeutics by 15.7% during the first quarter, owning approximately 1.08% of the company with a total value of $4.16 million.
• Several hedge funds, including Wellington Management Group and Frazier Life Sciences Management, have also significantly increased their stakes in Oruka, indicating strong institutional interest.
• Wall Street analysts overwhelmingly rate Oruka Therapeutics as a buy, with an average target price of $40.38 per share.

Jefferies Financial Group Inc. raised its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 15.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 405,029 shares of the company's stock after acquiring an additional 55,000 shares during the quarter. Jefferies Financial Group Inc. owned approximately 1.08% of Oruka Therapeutics worth $4,156,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ORKA. JPMorgan Chase & Co. acquired a new position in Oruka Therapeutics in the fourth quarter valued at approximately $54,000. Squarepoint Ops LLC acquired a new position in Oruka Therapeutics in the fourth quarter valued at approximately $236,000. Wellington Management Group LLP lifted its stake in Oruka Therapeutics by 15.8% in the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock valued at $1,844,000 after buying an additional 12,952 shares during the last quarter. Jane Street Group LLC purchased a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $343,000. Finally, Affinity Asset Advisors LLC lifted its stake in Oruka Therapeutics by 5.4% in the fourth quarter. Affinity Asset Advisors LLC now owns 368,698 shares of the company's stock valued at $7,149,000 after buying an additional 18,862 shares during the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Wednesday, July 23rd. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 22nd. BTIG Research assumed coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating for the company. Finally, Wedbush restated an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Monday, July 21st. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $40.38.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA traded up $0.70 during trading hours on Monday, hitting $14.30. The company's stock had a trading volume of 93,299 shares, compared to its average volume of 166,503. The business's 50-day moving average is $12.82 and its two-hundred day moving average is $11.38. The company has a market capitalization of $535.39 million, a PE ratio of -3.17 and a beta of -0.35. Oruka Therapeutics, Inc. has a 52-week low of $5.49 and a 52-week high of $52.32.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. As a group, analysts predict that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.